SRR8518316
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.570
- INFLAMMATORY_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.520
- MYC_TARGETS_V2+0.520
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_ALPHA_RESPONSE+0.470
- TNFA_SIGNALING_VIA_NFKB+0.470
- ANGIOGENESIS+0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
- OXIDATIVE_PHOSPHORYLATION+0.400
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.360
- TGF_BETA_SIGNALING-0.290
- UV_RESPONSE_DN-0.290
- ANDROGEN_RESPONSE-0.220
- ESTROGEN_RESPONSE_EARLY-0.200
- MITOTIC_SPINDLE-0.190
- APICAL_JUNCTION-0.180
- PROTEIN_SECRETION-0.140
- MYOGENESIS-0.110
- SPERMATOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O2-A52Q-01A-11R-A26W-07 | — | cohortA1 | 0.890 |
| 2 | TCGA-BT-A42F-01A-11R-A23W-07 | — | — | 0.872 |
| 3 | AUR-AF98-TTM1-A-1-1-R-A742-41 | — | E | 0.870 |
| 4 | TCGA-H7-8501-01A-11R-2403-07 | — | — | 0.863 |
| 5 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.859 |
| 6 | TCGA-GU-A766-01A-11R-A32O-07 | — | — | 0.855 |
| 7 | MNG1072 | — | — | 0.850 |
| 8 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.849 |
| 9 | TCGA-GC-A6I1-01A-12R-A31N-07 | — | — | 0.846 |
| 10 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |